Systematic review and meta-analysis of the effects of antipyretic medications on mortality in streptococcus pneumoniae infections

Postgraduate Medical Journal

Volumn 88, Issue 1035, 2012, Pages 21-27

  Jefferies, Sarah ^a,b   Weatherall, Mark ^b,c   Young, Paul ^b   Eyers, Sally ^a,c   Beasley, Richard ^a,b  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; SALICYLATE SODIUM; SALICYLIC ACID;

ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; DISEASE SEVERITY; DRUG SAFETY; EARLY INTERVENTION; FEVER; HUMAN; IN VIVO STUDY; META ANALYSIS; MORTALITY; NONHUMAN; PNEUMOCOCCAL INFECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; SYSTEMATIC REVIEW; THERAPY DELAY; TREATMENT OUTCOME;

ANIMALS; ANTIPYRETICS; ASPIRIN; BODY TEMPERATURE; DISEASE MODELS, ANIMAL; FEVER; HUMANS; PNEUMOCOCCAL INFECTIONS;

EID: 83755178433     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2011-130217     Document Type: Article

References (51)

1. Austrian R. Pneumococcus: the first one hundred years. Rev Infect Dis 1981;3:183-9.
2. Loewy A, Richter PF. Experimentelle Untersuchungen über die Heilkraft des Fiebers. Arch Pathol Anat 1896;145:49-77.
3. McDowell C. The effect of different temperatures and humidities on the resistance of rats to a pneumococcus infection. Am J Epidemiol 1923;3:521-46.
4. Rolly F, Meltzer KSO. Experimentelle Untersuchungen über die Bedeutung der Hyperthermie. Deutsch Arch klin Med 1908;94:335-64.
5. Walther P. Die Einwirkung der künstlichen Erhohung der Korpertemperatur auf den Verlauf der Infection durch Pneumonie-Diplococcen. Arch f Hyg 1891;12: S329-50.
6. Strouse S. Experimental studies on pneumococcus infections. J Exptl Med 1909;11:743-61.
7. Muschenheim C, Duerschner DR, Hardy JD, et al. Hypothermia in experimental infections. III. The effect of hypothermia on resistance to experimental pneumococcus infection. J Infect Dis 1942;72:187-96.
8. Sanders F, Crawford ES, De Bakey ME. Effects of hypothermia on experimental intracutaneous pneumococcal infection in rabbits. Surg Forum 1957;8:92-7.
9. Larson WP, Bieter RN, Levine M, et al. Temperature reactions in mice infected with pneumococci. Proc Soc Exp Biol Med 1939;42:649-51.
10. Eiseman B, Malette WG, Summers WB, et al. Prolonged hypothermia in experimental pneumococcal peritonitis. J Clin Invest 1956;35:940-6.
11. Wotkyns RS, Hirose H, Eiseman B. Prolonged hypothermia in experimental pneumococcal peritonitis. II. Survival of hypothermic animals and effect of combined hypothermia and antibiotics. Surg Gynecol Obstet 1958;107:363-9.
12. Rich AR, McKee CM. The mechanism of a hitherto unexplained form of native immunity to the type III pneumococcus. Bull Johns Hopkins Hosp 1936;59:171-207.
13. Shaffer MF, Enders JF, Wilson J. The effect of artificial fever and specific antiserum on the organisms present in cases of type III pneumococcus meningitis. J Clin Invest 1938;17:133-45.
14. Enders JF, Shaffer MF. Studies on natural immunity to pneumococcus type III. I. The capacity of strains of pneumococcus type III to grow at 41oC and their virulence for rabbits. J Exptl Med 1936;64:7-18.
15. Mackowiak PA, Ruderman AE, Martin RM, et al. Effects of physiologic variations in temperature on the rate of antibiotic-induced bacterial killing. Am J Clin Pathol 1981;76:57-62.
16. Bryant RE, Hood AF, Hood CE, et al. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 1971;127:120-8.
17. Weinstein MP, Iannini PB, Stratton CW, et al. Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved survival and factors influencing prognosis. Am J Med 1978;64:592-8.
18. Arons MM, Wheeler AP, Bernard GR, et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Crit Care Med 1999;27:699-707.
19. Kurosawa S, Kobune F, Okuyama K, et al. Effects of antipyretics in rinderpest virus infection in rabbits. J Infect Dis 1987;155:991-7.
20. Vaughn LK, Veale WL, Cooper KE. Antipyresis: its effect on mortality rate of bacterially infected rabbits. Brain Res Bull 1980;5:69-73.
21. van der Zee CE, van Dam RH, Dwinger RH, et al. Flurbiprofen and immunosuppression of Trypanosoma brucei infection in the goat. Vet Immunol Immunopathol 1985;8:341-50.
22. Doran TF, De Angelis C, Baumgardner RA, et al. Acetaminophen: more harm than good for chickenpox? J Pediatr 1989;114:1045-8.
23. Brandts CH, Ndjave M, Graninger W, et al. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet 1997;350:704-9.
24. Graham NM, Burrell CJ, Douglas RM, et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990;162:1277-82.
25. Stanley ED, Jackson GG, Panusarn C, et al. Increased viral shedding with aspirin treatment of rhinovirus infection. JAMA 1975;231:1248-51.
26. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009;374:1339-50.
27. Schulman CI, Namias N, Doherty J, et al. The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study. Surg Infect (Larchmt) 2005;6:369-75.
28. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl 3): iii1-55.
29. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374:893-902.
30. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57.
31. Whitehead A. Meta-analysis of Controlled Clinical Trials. Chichester: J Wiley & Sons, 2002.
32. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
33. Esposito AL. Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia. Am Rev Respir Dis 1984;130:857-62.
34. Klastersky J. Etude experimentale et clinique des effets favorables et defavorables de la fievre et de l'administration de corticoides au cours d'infections bacteriennes. Acta Clinica Belgica 1971;26:1-84.
35. Sande MA, Sande ER, Woolwine JD, et al. The influence of fever on the development of experimental Streptococcus pneumoniae meningitis. J Infect Dis 1987;156:849-50.
36. del Prado G, Martinez-Marin C, Huelves L, et al. Impact of ibuprofen therapy in the outcome of experimental pneumococcal acute otitis media treated with amoxicillin or erythromycin. Pediatr Res 2006;60:555-9.
37. Diven WF, Evans RW, Alper C, et al. Treatment of experimental acute otitis media with ibuprofen and ampicillin. Int J Pediatr Otorhinolaryngol 1995;33:127-39.
38. Ponte C, Parra A, Cenjor C, et al. Does acetaminophen interfere in the antibiotic treatment of acute otitis media caused by a penicillin-resistant pneumococcus strain? A gerbil model. Pediatr Res 2003;54:913-18.
39. Small PM, Tauber MG, Hackbarth CJ, et al. Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. Infect Immun 1986;52:484-7.
40. Spagnuolo PJ, Ellner JJ. Aspirin (ASA) inhibits in vitro human granulocyte adherence (GA) and chemotaxis (CX) and in vivo granulocyte response to experimental pneumococcal peritonitis. Clin Res 1977;25:588A.
41. Spagnuolo PJ, Ellner JJ. Aspirin (ASA) inhibits human granulocyte adherence in vitro and the inflammatory response to experimental pneumococcal peritonitis. Clin Res 1978;26:406A.
42. Spagnuolo PJ, Ellner JJ. Salicylate blockade of granulocyte adherence and the inflammatory response to experimental peritonitis. Blood 1979;53:1018-22.
43. Pandya U, Allen CA, Watson DA, et al. Global profiling of Streptococcus pneumoniae gene expression at different growth temperatures. Gene 2005;360:45-54.
44. Cafini F, Gonzalez N, Torrico M, et al. [Influence of the displacement of protein binding by ibuprofen in the activity of a third-generation cephalosporin against Streptococcus pneumoniae] (In Spanish). Rev Esp Quimioter 2006;19:332-6.
45. Stables MJ, Newson J, Ayoub SS, et al. Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood 2010;116:2950-9.
46. Roberts NJ Jr. Impact of temperature elevation on immunologic defenses. Rev Infect Dis 1991;13:462-72.
47. Watson DA, Musher DM, Jacobson JW, et al. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis 1993;17:913-24.
48. Hausdorff WP, Bryant J, Paradiso PR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-21.
49. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010;7:1-13.
50. Eyers S, Weatherall M, Shirtcliffe P, et al. The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis. J R Soc Med 2010;103:403-11.
51. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 2009;30:210-38.